


CLAIMS:

1. A compound of the formula



5

Sub
an

wherein A is an L, D or DL amino acid selected from the group consisting of Alanine (Ala), valine (Val), phenylalanine (Phe), para-chloro-phenylalanine (p.Cl Phe), tryptophan (Trp), proline (Pro), serine (Ser), Threonine (Thr), tyrosine (Tyr), glutamic acid (Glu), beta alanine (Beta Ala), -aminobutyric acid (Abu), N-methylalanine (N-Me Ala), 5-fluorotryptophan (5-F Trp), 5-bromotryptophan (5-Br Trp), 5-chlorotryptophan (5-Cl Trp), their acetylated derviatives or a pharmaceutically acceptable acid addition salt thereof;

10

15

B is an L, D or DL amino acid selected from the group consisting of threonine amid (Thr NH₂), valine amide (Val NH₂), proline amide (Pro NH₂), hydroxyproline amide (HO Pro NH₂), serine amide (Ser NH₂), tyrosine amide (Tyr NH₂, tryptophan amide (Trp NH₂), 5-fluorotryptophan amide (5-F Trp NH₂), formyl tryptophan amide (For Trp NH₂), alanine amide (Ala NH₂), glycine amide (Gly NH₂) and methylalanine amide (Me Ala NH₂);

20

X is L-phenylalanine (L-Phe) or L-tyrosine (L-Tyr);

25

Y is L-threonine (L-Thr) or L-valine (L-Val);

Z is L, D or DL 5-halo-tryptophan, in which the halogen (Halo-) is fluorine, chlorine, bromine or iodine, or D-tryptophan (D-Trp); and

C" and C' are L or D-cysteine (Cys), α -aminobutyric acid (Abu), aspartic acid (Asp) or lysine (Lys);

30

the connecting line between C" and C' signifies a bridge selected from the group consisting of carbon/carbon, carbon/sulfur, sulfur/sulfur and amide bridges; and the pharmaceutically acceptable acid addition salts thereof.

35

2. A compound according to Claim 1 wherein
C" is Cys;
X is Phe;
Z is D-Trp;
Y is Thr; and
C' is Cys.

3. A compound according to Claim 1 wherein
C" is Cys;
X is Tyr;
Z is D-Trp;
Y is Val; and
C' is Cys.

4. A compound according to Claim 1 wherein
C" is Cys;
X is Phe;
Y is Thr; and
C' is Cys.

5. A compound according to Claim 1 wherein
C" is Cys;
X is Tyr;
Y is Val; and
C' is Cys.

6. A compound according to Claim 1 wherein
C" is Lys;
X is Tyr;
Z is D-Trp;
Y is Val; and
C' is Asp.

7. A compound according to Claim 1 which is
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂.

8. A compound according to Claim 1 which is
Ac-p-Cl-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂.

6
B 7 A compound according to Claim 1 which is
T0420X ~~6-Cl~~-D-Phe-Cys-~~Trp~~-D-Trp-Lys-~~Thr~~-Cys-~~Thr~~-NH₂.


R.C. - A.V.S. 4-18

B 8 A compound according to Claim 1 which is
T0421X Ac-~~6-Cl~~-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂.

R.C. - A.V.S. 4-18


9 A compound according to Claim 1 which is
T0422X ~~Ac~~-D-Phe-Lys-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂ (amide bridge).

10 An octapeptide (reduced form) of the formula




wherein A, C'', X, Z, Y, C' and B are as defined in Claim 1.


11 A compound according to Claim 1 which is:



12 A compound according to Claim 1 which is:




13 A compound according to Claim 1 which is:




R.C. A.V.S. 4-18

14 A process for preparing an octapeptide of formula (I)



in which A, C'', X, Z, Y, C' and B are as defined in Claim 1 which comprises oxidizing a corresponding peptide of formula (II)



in which A, C'', X, Z, Y, C' and B are as defined above.

15 The process of Claim 14 wherein the peptide of formula (I') is oxidized with potassium ferricyanide, iodine, oxygen or air.

B

14
18.

A pharmaceutical composition which comprises an octapeptide of Claim 1, its reduced form or a pharmaceutically acceptable acid addition salt thereof in a pharmaceutically acceptable liquid or solid carrier thereof.

15

19. A pharmaceutical composition of Claim 14 which

~~comprises an octapeptide of Claim 1, its reduced form or a pharmaceutically acceptable acid addition salt thereof,~~
encapsulated in poly (d,l-lactide-co-glycolide) microcapsules.

16


20. A method of treating excess release of growth

hormone, gastrointestinal disorders, ~~cancer~~ and diabetes in a mammal in need of such therapy which comprises administering to said mammal an effective dose of octapeptide of Claim 1, its reduced form, or a pharmaceutically acceptable acid addition salt thereof.

(P.C.-Arg)
(P.C.-Arg)
(P.C.-Arg)
(4/18/85)

13
21

A COMPOUND ACCORDING TO CLAIM 12 WHICH IS:



add B17

43